MX2025001036A - Composicion farmaceutica que comprende un inhibidor de kras g12d - Google Patents
Composicion farmaceutica que comprende un inhibidor de kras g12dInfo
- Publication number
- MX2025001036A MX2025001036A MX2025001036A MX2025001036A MX2025001036A MX 2025001036 A MX2025001036 A MX 2025001036A MX 2025001036 A MX2025001036 A MX 2025001036A MX 2025001036 A MX2025001036 A MX 2025001036A MX 2025001036 A MX2025001036 A MX 2025001036A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- kras
- inhibitor
- present disclosure
- disclosure relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente descripción se refiere a una composición farmacéutica que comprende un inhibidor de KRAS G12D. En particular, la presente descripción se refiere a una composición farmacéutica, que comprende un compuesto representado por la fórmula I o una sal farmacéuticamente aceptable del mismo, y un lípido. La composición farmacéutica puede aplicarse mejor clínicamente. (ver Fórmula).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210909959 | 2022-07-29 | ||
| CN202211642769 | 2022-12-20 | ||
| PCT/CN2023/109901 WO2024022507A1 (zh) | 2022-07-29 | 2023-07-28 | 一种包含kras g12d抑制剂的药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025001036A true MX2025001036A (es) | 2025-03-07 |
Family
ID=89705462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025001036A MX2025001036A (es) | 2022-07-29 | 2025-01-24 | Composicion farmaceutica que comprende un inhibidor de kras g12d |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4563151A4 (es) |
| JP (1) | JP2025524799A (es) |
| KR (1) | KR20250037564A (es) |
| CN (1) | CN119384279A (es) |
| AU (1) | AU2023314335A1 (es) |
| CA (1) | CA3261035A1 (es) |
| MX (1) | MX2025001036A (es) |
| TW (1) | TW202408536A (es) |
| WO (1) | WO2024022507A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| CN119365467A (zh) | 2022-05-19 | 2025-01-24 | 基因泰克公司 | 氮杂-四环氧氮杂䓬化合物及其用途 |
| AU2023320565A1 (en) | 2022-08-05 | 2025-01-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9968570B2 (en) * | 2013-01-14 | 2018-05-15 | Chemo-Enhanced Llc | Compositions and methods for treating cancer |
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| CN114615981B (zh) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| CN112745335B (zh) * | 2019-10-30 | 2024-08-30 | 武汉誉祥医药科技有限公司 | 一种三并杂环化合物及其用途 |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| WO2021203768A1 (zh) * | 2020-04-08 | 2021-10-14 | 江苏恒瑞医药股份有限公司 | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 |
| WO2022017339A1 (zh) * | 2020-07-20 | 2022-01-27 | 江苏恒瑞医药股份有限公司 | 稠合哒嗪类衍生物、其制备方法及其在医药上的应用 |
| US20240199644A1 (en) * | 2021-03-07 | 2024-06-20 | Jacobio Pharmaceuticals Co., Ltd. | Fused Ring Derivatives Useful as KRAS G12D Inhibitors |
| CN117043167A (zh) * | 2021-03-17 | 2023-11-10 | 劲方医药科技(上海)有限公司 | 嘧啶并环类化合物及其制法和用途 |
| MX2023015533A (es) * | 2021-06-21 | 2024-01-23 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. |
| CN117677624A (zh) * | 2021-07-19 | 2024-03-08 | 上海艾力斯医药科技股份有限公司 | 新型吡啶并嘧啶衍生物 |
| CA3226720A1 (en) * | 2021-07-23 | 2023-01-26 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
-
2023
- 2023-07-28 KR KR1020257005566A patent/KR20250037564A/ko active Pending
- 2023-07-28 CN CN202380046186.1A patent/CN119384279A/zh active Pending
- 2023-07-28 EP EP23845711.3A patent/EP4563151A4/en active Pending
- 2023-07-28 TW TW112128471A patent/TW202408536A/zh unknown
- 2023-07-28 WO PCT/CN2023/109901 patent/WO2024022507A1/zh not_active Ceased
- 2023-07-28 CA CA3261035A patent/CA3261035A1/en active Pending
- 2023-07-28 AU AU2023314335A patent/AU2023314335A1/en active Pending
- 2023-07-28 JP JP2025501568A patent/JP2025524799A/ja active Pending
-
2025
- 2025-01-24 MX MX2025001036A patent/MX2025001036A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023314335A1 (en) | 2025-02-27 |
| EP4563151A4 (en) | 2025-11-05 |
| KR20250037564A (ko) | 2025-03-17 |
| CA3261035A1 (en) | 2025-04-04 |
| TW202408536A (zh) | 2024-03-01 |
| CN119384279A (zh) | 2025-01-28 |
| EP4563151A1 (en) | 2025-06-04 |
| JP2025524799A (ja) | 2025-08-01 |
| WO2024022507A1 (zh) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200608972A (en) | Aryl-pyridine derivatives | |
| SG148178A1 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
| UA94052C2 (uk) | Похідні піридазину | |
| MX2010006799A (es) | Benzofuropirimidinonas como inhibidores de la proteina cinasa. | |
| MX2009003939A (es) | Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes. | |
| MX2010005824A (es) | Derivados de aminotiazol. | |
| TNSN06377A1 (en) | Combinations of glycopyrrolate and beta2 adrenoceptor agonists | |
| IN2012DN03337A (es) | ||
| DE602005013793D1 (de) | Thiazolderivate mit vap-1-hemmender wirkung | |
| MX2024007242A (es) | Lipido y composicion utilizada para la administracion. | |
| PH12023552774A1 (en) | Nek7 inhibitors | |
| MX2009009849A (es) | Derivados de piridazinona sustituida con piperazina utiles como inhibidores de glucano sintasa. | |
| SG2013013339A (en) | N3 alkylated benzimidazole derivatives as mek inhibitors | |
| MX2008016426A (es) | Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1). | |
| ZA202401684B (en) | Novel parp7 inhibitor and use thereof | |
| WO2020063696A8 (zh) | 胺基脲敏感性胺氧化酶抑制剂制备及其应用 | |
| MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
| PH12022550531A1 (en) | Irak inhibitor and preparation method therefor and use thereof | |
| TW200616958A (en) | New alkyl-pyridines as 11-beta inhibitors for diabetes | |
| PH12022551241A1 (en) | Egfr inhibitors | |
| MX2009003169A (es) | Derivados de sulfonamida. | |
| MX2023013225A (es) | Inhibidores de la cinasa 4 similar a polo. | |
| MX2023012004A (es) | DERIVADO DEL ÁCIDO BÓRICO QUE ACTÚA COMO INHIBIDOR DE LA ß-LACTAMASA. | |
| UY27930A1 (es) | Derivados de tiazol | |
| MY147188A (en) | Substituted imidazole compounds as ksp inhibitors |